30-Day Readmission Linked to Higher Mortality for Glioblastoma Patients

Patients with glioblastoma multiforme, malignant brain tumors, readmitted in 30 days of admission experience shorter survival rates than patients who are not readmitted, according to a study in Neurosurgery.

Researchers analyzed data on gliblastoma multiforme patients nationwide diagnosed between 1991 and 2007 in the Surveillance, Epidemiology and End Results Medicare database. They found 15.8 percent of patients were readmitted within 30 days. The median survival time for readmitted patients was six months, compared to 7.6 months for nonreadmitted patients. Readmission increased mortality rates by 30 percent.

Researchers suggest future studies are needed to help reduce readmissions and evaluate the impact readmissions have on patient outcomes.

More Articles on Readmissions:

Study: 15% of Avoidable Readmissions Linked to End-of-Life Care Issues
Readmission Rates Constant for Different Prostate Surgery Techniques
SSI Most Powerful Predictor of Surgical Readmission

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.